nach oben

Erschienen in:

01.12.2009

The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30

verfasst von: Ophira M. Ginsburg, Mohammad R. Akbari, Zeba Aziz, Robert Young, Henry Lynch, Parviz Ghadirian, Andre Robidoux, Julian Londono, Gonzalo Vasquez, Magda Gomes, Mauricio Magalhaes Costa, Constantine Dimitrakakis, Gustavo Gutierrez, Robert Pilarski, Robert Royer, Steven A. Narod

Erschienen in: Familial Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Germ-line mutations in the TP53 gene are rare, but predispose women to a range of cancer types, including early-onset breast cancer. Breast cancers in women from families with the Li-Fraumeni syndrome often occur before age 30. The prevalence of deleterious TP53 mutations in unselected women with early-onset breast cancer is not precisely known. If mutations were found to be sufficiently common, it might be prudent to offer genetic testing to affected women in this age group. We screened the entire TP53 gene in the germ-line DNA from 95 women of various ethnic groups who were diagnosed with breast cancer before age 30, and who had previously been found to be negative for BRCA1 and BRCA2 mutations. No TP53 mutation was found. This study does not support a policy that TP53 testing should be offered routinely to unselected women with early-onset breast cancer in the absence of a family history of cancer.

Narod SA, Foulkes WD (2004) BRCA1 and BRCA2; 1994 and beyond. Nat Rev Cancer 4:665–676CrossRefPubMed

Li FP, Fraumeni JF Jr (1969) Soft tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752PubMed

Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362PubMed

Garber JE, Goldstein AM, Kantor AF et al (1991) Follow up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51:6069–6097

Malkin D, Li FP, Strong LC et al (1990) Germline p53 mutations in a familial syndrome of breast cancer, sarcoma, and other neoplasms. Science 250:1233–1238CrossRefPubMed

Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298–1304PubMed

Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, Abeliovich D, Peretz T (2007) Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clin Oncol (R Coll Radiol) 19(7):490–493

De Leon Matsuda ML, Liede A, Kwan E, Mapua CA, Cutiongco EM, Tan A, Borg A, Narod SA (2002) BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 98(4):596–603CrossRefPubMed

Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA (2002) Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 71(3):595–606CrossRefPubMed

10.

Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103(3):349–353CrossRefPubMed

11.

Rozen S, Skaletsky HJ (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics methods and protocols: methods in molecular biology. Humana Press, New Jersey, pp 365–386

12.

Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site detection in Genie. J Comput Biol 4(3):311–323CrossRefPubMed

13.

Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR (2006) An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15(16):2490–2508CrossRefPubMed

14.

Manoukian S, Peissel B, Pensotti V et al (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43(3):601–606CrossRefPubMed

15.

Krasteva ME, Georgieva EI (2006) Germline p53 single-base changes associated with Balkan endemic nephropathy. Biochem Biophys Res Commun 342(2):562–567CrossRefPubMed

16.

Keller G, Vogelsang H, Becker I et al (2004) Germline mutations of the E-cadherin (CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 41(6):e89CrossRefPubMed

17.

Dearth LR, Qian H, Wang T et al (2007) Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28(2):289–298CrossRefPubMed

18.

Shiraishi K, Kato S, Han SY et al (2004) Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279(1):348–355CrossRefPubMed

19.

Resnick MA, Inga A (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100(17):9934–9939CrossRefPubMed

20.

Monti P, Campomenosi P, Ciribilli Y et al (2003) Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22(34):5252–5260CrossRefPubMed

21.

Maurici D, Monti P, Campomenosi P et al (2001) Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20(27):3533–3540CrossRefPubMed

22.

Smith PD, Crossland S, Parker G et al (1999) Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 18(15):2451–2459CrossRefPubMed

23.

Flaman JM, Robert V, Lenglet S et al (1998) Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 16(10):1369–1372CrossRefPubMed

24.

Tinat J, Bougeard G, Baert-Desurmont et al (2009) 2009 version of the Chompret criteria for Li-Fraumeni syndrome. J Clin Oncol (Epub August)

25.

Borresen A-L, Andersen TI, Garber J et al (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234–3236PubMed

26.

Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:10–24

27.

Laloo F, Varley J, Moran A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143–1150CrossRef

28.

Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fung CY, Nguyen Q, Han JH et al (2009) Beyond Li-Fraumeni syndrome, clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250–1256CrossRefPubMed

29.

Bougeard G, Sesboue R, Baert-Desurmont S et al (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45(8):535–538CrossRefPubMed

30.

Evans DG, Wu CL, Birch JM (2008) BRCA2: a cause of the Li-Fraumeni like syndrome. J Med Genet 45:62–63CrossRefPubMed

31.

Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2 and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388CrossRefPubMed

Titel: The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
verfasst von: Ophira M. Ginsburg
Mohammad R. Akbari
Zeba Aziz
Robert Young
Henry Lynch
Parviz Ghadirian
Andre Robidoux
Julian Londono
Gonzalo Vasquez
Magda Gomes
Mauricio Magalhaes Costa
Constantine Dimitrakakis
Gustavo Gutierrez
Robert Pilarski
Robert Royer
Steven A. Narod
Publikationsdatum: 01.12.2009
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 4/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-009-9287-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis

Genetic polymorphism in ornithine decarboxylase and risk of breast cancer

Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population

FAP-associated desmoid invasiveness correlates with in vitro resistance to doxorubicin

Impact of 226C>T MSH2 gene mutation on cancer phenotypes in two HNPCC-associated highly-consanguineous families from Kuwait: emphasis on premarital genetic testing

First case report of Muir–Torre syndrome associated with non-small cell lung cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie